Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. develops, manufactures and commercializes neuromodulation medical devices for cardiovascular disease. Its Barostim therapy is an implantable system that delivers electrical pulses to carotid baroreceptors to rebalance autonomic nervous system signaling and improve symptoms in heart failure patients.
Company updates commonly cover Barostim commercialization in the United States and Europe, FDA approval and Breakthrough Device history, CE Mark status for heart failure and resistant hypertension in the European Economic Area, clinical data from heart failure studies, reimbursement and coding developments, quarterly operating results, financing activity and board governance matters.
CVRx, Inc. has successfully closed its initial public offering (IPO) of 8,050,000 shares of common stock at $18.00 per share, generating approximately $144.9 million in gross proceeds. This includes an additional 1,050,000 shares exercised by underwriters. The stock began trading on Nasdaq under the ticker CVRX on June 30, 2021. The IPO was facilitated by J.P. Morgan, Piper Sandler, and William Blair as joint book-running managers.